Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

Primary biliary cholangitis (PBC) is a rare liver disease. It blocks and destroys bile ducts in the liver. Doctors used to call it “primary biliary cirrhosis.” “Biliary” means bile.

Learn about Primary Biliary Cholangitis, its causes, symptoms like fatigue and itching and treatment options including ...

New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...

This is the reality for some people living with primary biliary cholangitis (PBC). “The symptoms aren’t always obvious,” shares Naveen, a patient with PBC. “There haven’t been many ...

Primary biliary cholangitis (PBC) causes chronic inflammation and progressive destruction of the bile ducts, resulting in cholestatic pruritus—a severe internal itch that scratching cannot relieve.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

If this continues, it can lead to serious liver problems and even liver failure. Primary biliary cholangitis, formerly known as primary biliary cirrhosis, is an autoimmune disease that causes ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis. Results from an interim ...